Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
|MOB-1117z||Mouse Anti-IGHG1 Recombinant Antibody (clone 5C2)||FC, IF, IHC, WB||Mouse IgG1, κ|
|MOB-034LC||Mouse Anti-IGHG1 Recombinant Antibody (clone YC121)||ELISA, WB, IHC||Mouse IgG|
|MOR-1394||Rabbit Anti-IGHG1 Recombinant Antibody (clone DS1394AB)||ICC, IHC, FC, ELISA||Rabbit IgG|
|MOR-1771||Rabbit Anti-IGHG1 Recombinant Antibody (clone DS1771AB), PE||FC||Rabbit IgG|
|EPAF-0577CQ||Mouse Anti-IGHG1 Recombinant Antibody (clone B3-18)||ELISA||Mouse IgM|
There are currently no Customer reviews or questions for TP-095CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.